Zoetis Inc. (NYSE:ZTS) Stock Rated "Hold" by Wall Street Analysts

Key Points

• Analysts rate Zoetis “Hold” overall: Of 19 analysts, nine recommend holding, eight recommend buying and two recommend selling. The average 12-month price target is $101.08.
• Several firms recently lowered their price targets, with targets ranging from $80 to $96 while maintaining mostly “buy” or “neutral” ratings.
• Zoetis reported quarterly EPS of $1.87, slightly exceeding estimates, while revenue of $2.47 billion fell just short of expectations and declined 0.2% year over year. Institutional investors own approximately 92.8% of the stock.

Zoetis Inc. (NYSE:ZTS - Get Free Report) has received a consensus rating of "Hold" from the nineteen research firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $101.08.

Several equities research analysts have commented on ZTS shares. Cantor Fitzgerald set a $94.00 price target on shares of Zoetis in a research note on Tuesday, August 25th. Citigroup reduced their price objective on Zoetis from $112.00 to $96.00 and set a "buy" rating for the company in a research report on Tuesday, August 11th. TD Cowen decreased their price objective on Zoetis from $104.00 to $94.00 and set a "buy" rating for the company in a report on Tuesday, August 25th. UBS Group lowered their target price on Zoetis from $85.00 to $80.00 and set a "neutral" rating on the stock in a research report on Friday, August 7th. Finally, Piper Sandler cut their target price on Zoetis from $90.00 to $80.00 and set a "neutral" rating on the stock in a research note on Monday, August 10th.

Zoetis Stock Performance

ZTS stock opened at $69.76 on Thursday. Zoetis has a 1 year low of $69.52 and a 1 year high of $148.79. The stock has a market capitalization of $28.83 billion, a price-to-earnings ratio of 11.49, a PEG ratio of 1.64 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The stock's fifty day moving average is $74.62 and its two-hundred day moving average is $86.89.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company's quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts predict that Zoetis will post 6.2 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. State Street Corp lifted its holdings in Zoetis by 1.8% in the second quarter. State Street Corp now owns 19,667,723 shares of the company's stock worth $1,413,323,000 after purchasing an additional 343,322 shares during the period. Tidal Investments LLC grew its position in Zoetis by 22.8% in the 2nd quarter. Tidal Investments LLC now owns 493,507 shares of the company's stock valued at $35,463,000 after buying an additional 91,492 shares in the last quarter. National Pension Service increased its stake in Zoetis by 9.6% during the 2nd quarter. National Pension Service now owns 839,875 shares of the company's stock valued at $60,353,000 after buying an additional 73,785 shares during the period. WINTON GROUP Ltd acquired a new position in Zoetis during the 2nd quarter valued at about $223,000. Finally, Engineers Gate Manager LP raised its position in shares of Zoetis by 3,551.3% during the 2nd quarter. Engineers Gate Manager LP now owns 107,678 shares of the company's stock worth $7,738,000 after buying an additional 104,729 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.